ArticleClinical microbiology reviews2012
New approaches to sepsis: molecular diagnostics and biomarkers.
Article in Clinical microbiology reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02533011 (Heparin Binding Protein), which is not on this map. Cited by 231 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Heparin Binding Protein (HBP) in Sepsis for the Prediction of Disease Progression
Who cites it
231 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Prognostic role of elevated VEGF in sepsis: A systematic review and meta-analysis.Frontiers in physiology · 2022Pooled it
- Potential Targets to Mitigate Trauma- or Sepsis-Induced Immune Suppression.Frontiers in immunology · 2021Pooled it
- Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis.BMC infectious diseases · 2019Pooled it
- Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis.BMC infectious diseases · 2017Pooled it
- Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis.BMC infectious diseases · 2017Pooled it
- Relationship of serum mannose-binding lectin levels with the development of sepsis: a meta-analysis.Inflammation · 2015Pooled it
- Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial.Intensive care medicine · 2017Trial
- Trial
- Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome.Critical care (London, England) · 2017Trial
- Microbial proteases and endothelial barrier disruption in sepsis: A neglected nexus.Virulence · 2026Review
- Article
- Preliminary Single-Center Evaluation of the Alifax Molecular Mouse Sepsis Panel for Rapid Detection of Bloodstream Pathogens.Diagnostics (Basel, Switzerland) · 2026Article
- Host-pathogen interactions during ESKAPE-mediated urinary tract infections and ventilator-associated pneumonia: a review.Folia microbiologica · 2026Review
- Review
- Association of CD4+/CD8+ T Cell Subsets and Cytokine Profiles with Clinical Outcomes in COVID-19.Pakistan journal of medical sciences · 2026Article
- SIRPα extracellular domain shed from neutrophils by ADAM10 aggravates sepsis via initiating nitric oxide release from erythrocyte.Journal of advanced research · 2026Article
- Proteomic biomarkers for early diagnosis and prognosis in pediatric sepsis.World journal of clinical pediatrics · 2026Article
- The role of rapid molecular diagnostics in managing bloodstream infections: a microbiological insight.Folia microbiologica · 2026Review
- Sepsis-induced immunothrombosis: from cellular crosstalk to multiple organ dysfunction.Frontiers in immunology · 2026Review
- Adjudication instrument for infection in critically injured trauma patients.Trauma surgery & acute care open · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is among the most common causes of death in hospitals. It arises from the host response to infection. Currently, diagnosis relies on nonspecific physiological criteria and culture-based pathogen detection. This results in diagnostic uncertainty, therapeutic delays, the mis- and overuse of antibiotics, and the failure to identify patients who might benefit from immunomodulatory therapies. There is a need for new sepsis biomarkers that can aid in therapeutic decision making and add information about screening, diagnosis, risk stratification, and monitoring of the response to therapy. The host response involves hundreds of mediators and single molecules, many of which have been proposed as biomarkers. It is, however, unlikely that one single biomarker is able to satisfy all the needs and expectations for sepsis research and management. Among biomarkers that are measurable by assays approved for clinical use, procalcitonin (PCT) has shown some usefulness as an infection marker and for antibiotic stewardship. Other possible new approaches consist of molecular strategies to improve pathogen detection and molecular diagnostics and prognostics based on transcriptomic, proteomic, or metabolic profiling. Novel approaches to sepsis promise to transform sepsis from a physiologic syndrome into a group of distinct biochemical disorders and help in the development of better diagnostic tools and effective adjunctive sepsis therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.